|
Synonyms: APN01 | GSK-2586881 | GSK2586881 | rhsACE2
Compound class:
Peptide or derivative
Comment: Alunacedase alfa (APN01; Aperion Biologics) is a recombinant version of human ACE2 that is intended to act as a decoy (soluble trap) for the SARS-CoV-2 spike protein [1,4-5], than can neutralise the virus [4]. Recombinant ACE2 was originally proposed as a mechanism to combat acute respiratory distress syndrome (ARDS) caused by the SARS-CoV virus [2], which like SARS-CoV-2 uses ACE2 to infect host cells. Structurally APN01 is a glycosylated dimer of peptide chains that form the extracellular domain of the enzyme. It is produced in Chinese hamster ovary (CHO) cells, and it contains several intra-subunit disulphide bridges.
|
| References |
|
1. Abd El-Aziz TM, Al-Sabi A, Stockand JD. (2020)
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19. Signal Transduct Target Ther, 5 (1): 258. [PMID:33144565] |
|
2. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H et al.. (2005)
Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436 (7047): 112-6. [PMID:16001071] |
|
3. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M et al.. (2017)
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care, 21 (1): 234. [PMID:28877748] |
|
4. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F et al.. (2020)
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 181 (4): 905-913.e7. [PMID:32333836] |
|
5. Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C et al.. (2020)
Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med, 8 (11): 1154-1158. [PMID:33131609] |
